Brenig
4 employees on LinkedIn Β· 4 known investors
Brenig Therapeutics is a biotechnology company developing small-molecule therapies for Parkinson's disease and other neurodegenerative disorders, using AI-driven drug discovery. Its pipeline includes BT-267, a brain-penetrant LRRK2 inhibitor, and BT-409, an NLRP3 inflammasome inhibitor.
Founders & leadership
MM
Megan McGillChief Executive Officer
ID
Iain DukesChief Business Officer / Chairman of the Board
NS
Nikolay SavchukChief Operating Officer
TD
Tien DamChief Medical Officer
Investors Β· 4
Frequently asked questions
- What does Brenig do?
- Brenig Therapeutics is a biotechnology company developing small-molecule therapies for Parkinson's disease and other neurodegenerative disorders, using AI-driven drug discovery. Its pipeline includes BT-267, a brain-penetrant LRRK2 inhibitor, and BT-409, an NLRP3 inflammasome inhibitor.
- Who are Brenig's investors?
- Brenig's investors include New Enterprise Associates (NEA), OrbiMed, BGV, Torrey Pines Investment.